Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
6don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Novo Nordisk (NVO) has released an update. Novo Nordisk, a leading global healthcare company, recently reported that its board members and ...
Bagsværd, Denmark, 8 November 2024 - Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares ...
Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1 ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, acquiring 6.31 million B shares from Novo Holdings ...
Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback